Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Key Highlights
- ➤EVERGREEN Phase 3 initiation now expected in fourth quarter of 2026
- ➤JUNIPER Phase 2 interim data now expected in second quarter of 2027
- ➤JADE101 posters present planned Phase 3 and ongoing Phase 2 IgAN studies
- ➤Model-based analyses support JADE101 dose selection and accelerated development
Expert Statements
Andrew King, President, Research & Development of Jade Biosciences
“The anticipated initiation of EVERGREEN ahead of schedule reflects the disciplined execution of an experienced team to efficiently advance the JADE101 IgA nephropathy program into Phase 3 development.”
Andrew King, President, Research & Development of Jade Biosciences
“The presentations at ASN add to the growing body of evidence that has strengthened our conviction in JADE101’s potential best-in-class profile, characterized by potent, rapid and deep IgA reductions predicted to be sustained with convenient quarterly dosing.”
* EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026
* JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing study of JADE101 in IgA nephropathy; interim data now expected in the second quarter of 2027 SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that three posters related to JADE101, a novel, ultra-high affinity and half-life extended investigational anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody in development for the treatment of immunoglobulin A nephropathy (IgAN), will be presented at the American Society of Nephrology (ASN) Kidney Week 2026, being held in Denver, Colorado from October 21-25, 2026. The presentations highlight both the scientific foundation and continued clinical advancement of the JADE101 program in IgAN, including the planned acceleration of the EVERGREEN Phase 3 clinical trial, with initiation now expected in the fourth quarter of 2026.
Get started
Create a free account to read the full story.